PolyPid

PYPD · NASDAQ

$5.15+$0.27 (+5.53%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.88

About PYPD

PolyPid Ltd. operates as a phase 3 biopharma company. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 69 full-time employees. The company went IPO on 2020-06-26. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Employees: 69
Headquarters: Petah Tikva, Central(HaMerkaz)
Listed: Jun 26, 2020
Sector: Health Care
Industry: Pharmaceuticals
Website: polypid.com

Leadership

PolyPid executives
Name	Title	Since	Age
Brooke Story	—	2025	53
Dikla Akselbrad	—	2014	50
Shaul Mukhtar	—	—	66
Dalit Hazan	—	—	51
Noam Emanuel	—	2008	62
Ori Warshavsky	—	—	44
Yechezkel Barenholz	—	—	79
Nir Dror	—	—	48
Chaim Hurvitz	—	—	65
Itzhak Krinsky	—	—	69
Anat Segal	—	—	55
Robert Stein	—	—	74

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

PolyPid suppliers and customers
Company	Relationship	Country	Correlation
CTG Weld Ltd.	Supplier and customer	CY	—
Aurum Ventures M.K.I. Ltd.	Supplier and customer	IL	—
Shavit Capital Management Ltd	Supplier and customer	IL	—

Similar companies

Companies in the same industry as PolyPid

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.